Quan Zhou Ph.D. serves as Independent Director of the Company. Dr. Zhou has been a director of the Company since June 2016. Dr. Zhou served as the president of IDG Technology Venture Investment Inc. since mid-1990’s until 2012. He has been the managing member of IDG Technology Venture Investments, LP and its successor fund since 2000 and the director of various IDG-Accel China funds since 2005. He currently also serves as director of IDG China Venture Capital Fund IV L.P and its successor fund and IDG China Capital Fund III L.P. He is a member of the board of directors of a number of private and listed companies, including CosmoChina Limited, COFCO Womai Limited, Circle Internet Financial Limited and Yirendai Ltd (NYSE YRD). He has won awards from NASA and holds two U.S. Patents in fiber optic devices. Benefiting from more than 20 years of successful financing, business and operation experience, he has established close connections with numerous IT companies and entrepreneurial communities in both China and the United States. He received a Ph.D. in Fiber Optics from Rutgers University in 1989, a Master’s Degree in Chemical Physics from the Chinese Academy of Science and Technology University in 1982.
As the Independent Director of CASI Pharmaceuticals Inc, the total compensation of Quan Zhou at CASI Pharmaceuticals Inc is $139,000. There are 9 executives at CASI Pharmaceuticals Inc getting paid more, with Wei-Wu He having the highest compensation of $9,269,690.
Quan Zhou is 62, he's been the Independent Director of CASI Pharmaceuticals Inc since 2016. There are 3 older and 6 younger executives at CASI Pharmaceuticals Inc. The oldest executive at CASI Pharmaceuticals Inc is Rajesh Shrotriya, 76, who is the Independent Director.
Quan's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DR. SUITE 300, ROCKVILLE, MD, 20850.
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya és Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: